HONG KONG, May 29, 2019 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), the largest cardio-cerebral vascular ("CCV") drug manufacturer in China's prescription drug market, announced the third generation of EGFR inhibitor XZP-5809, a Category 1 innovative drug...
from PR Newswire: https://prn.to/2VXQ9M9
No comments:
Post a Comment